The CEO of a $40 billion healthcare data company just cashed out $26 million in shares at the exact moment the firm posted record bookings of $3.15 billion. Usually, a CEO sells after great news because they think the stock price has gotten ahead of itsel

Verdict: Wait — A Sound Thesis Trapped by an Unreachable Entry

The idea of buying a high-quality healthcare data franchise after a momentum flush is sound in theory, and IQVIA's fundamentals genuinely back it — the company posts an operating margin of 13.4% (87th percentile among peers) and $2.05 billion in annual free cash flow (99th percentile). But the strategy designed to capture that dip has produced zero triggers across 1,236 evaluated daily bars spanning 60 months, because all four of its required conditions — a close above the lower Bollinger Band, RSI below 45, a MACD bullish crossover, and positive OBV — have never aligned at once. Today, IQV's RSI sits at 67.4 against a required ceiling of 45, a gap of 22.4 points that underscores how far current conditions are from the entry zone. Furthermore, no robust parameter setup was established from the sensitivity analysis, which exhausted its time budget without testing a single variant, leaving the strict thresholds in place with no adjusted alternative. The thesis is intelligent and patient, but the rules are waiting for an oversold reset that the tape is not offering, and the company's debt-to-equity of 2.14 with a current ratio of just 0.75 means any pullback could be deeper than a routine technical correction. **Conviction Breakdown:** - **Thesis support (38/100):** The macro rotation narrative is coherent, but the CEO's $26.1 million sale cuts against the bullish dip-buying thesis, and IQV's 5.9% revenue growth lands in only the 34th percentile of healthcare peers. - **Trade readiness (20/100):** Zero entries across 1,236 evaluated bars over 60 months is the dominant fact; the multi-condition gate has never been satisfied in concert. - **Risk quality (35/100):** The 2.4% stop-loss is tight for a leveraged name with sub-1.0 current ratio and $729 million in annual interest expense, and could be breached in a single volatile session. - **Trigger proximity (15/100):** IQV RSI at 67.4 needs to fall below 45 (a 22.4-point gap); OBV is unreported; the setup is far from firing. - **Fundamentals trend (72/100):** IQVIA shows genuine operating strength with an 87th-percentile operating margin, 99th-percentile free cash flow, and 21% ROE, though leverage is elevated.

Trade now

IQV closed at $235.02, but the strategy's four-part entry has not fired — and the main holdup is momentum. RSI (14) sits at 67.4, and the entry needs it below 45, a gap of 22.4 points. Price is comfortably above the lower Bollinger Band at $214.94 (condition met), but the MACD bullish-crossover condition is not yet active (near, not triggered), and OBV is not currently reported. Translation: IQV is trending strong near its highs, not pulling back into the oversold zone this setup is built for. The thesis argues the stock is a pullback candidate after the CEO's $26 million sale, but the rules are waiting for evidence of that pullback materializing — right now, the tape says the opposite. For XLF, the picture is closer but still short. Price at $56.94 is above the lower Bollinger Band at $56.62 (met), but RSI at 53.8 needs to drop below 45 — a gap of 8.8 points. MACD crossover is near but not triggered. The financials rotation thesis is interesting here because XLF is the safe-haven side of the pair, yet its own entry rules also require an oversold read that hasn't arrived. **What to do today: wait.** No entry conditions are live for either ticker. For IQV, the stop would sit below the second support level at $214.01, and the fixed stop fires at -2.4% (roughly $229.4 from current price). The take-profit target is +4.8% (roughly $246.33) or the 127.2% Fibonacci extension, whichever comes first. That works out to approximately a 2:1 reward-to-risk ratio — but none of it matters until RSI cools off and MACD turns up from below. The parameter-sensitivity screen timed out before identifying a relaxed setup, so no adjusted thresholds are available; trade the published levels or stand aside. The research author flagged that the current thresholds may be too strict given zero triggers over 1,236 evaluated daily bars and requested bounded optimization to widen the RSI ceiling and related parameters. Until that produces a recommended variant, the watch levels below are your trigger map.

The fundamental and macro backdrop still support a defensive rotation

The core thesis leans on a macro rotation: Goldman Sachs expects S&P 500 volatility to climb ahead of the U.S. midterm elections, and per MarketWatch, investors are already rotating into financial stocks as a haven. The strategy rules are designed to wait for a technical pullback to support before entering long — a patient approach that fits an environment where the idea argues growth stocks are vulnerable. Importantly, the entry conditions have not triggered in the evaluated window of 1,236 daily bars, so this is a watch-list setup rather than an active signal; the strategy is waiting for IQV to…

Scores

• Conviction score breakdown: 36
• Thesis support: 38
• Trade readiness: 20
• Risk quality: 35
• Trigger proximity: 15
• Fundamentals trend: 72

Watch items

• IQV — RSI (14)
• IQV — MACD (12,26,9) crossover
• IQV — Price vs lower Bollinger Band
• IQV — Resistance at $234.30
• XLF — RSI (14)
• XLF — MACD (12,26,9) crossover
• IQV — Price above Bollinger (20)
• IQV — RSI (14) below 45
• IQV — MACD (12,26,9) crossed above MACD (12,26,9)
• XLF — Price above Bollinger (20)
• XLF — RSI (14) below 45